VNS RESULTS:

• Adolescent Data (EO1-EO5)
• Efficacy Results
• Adverse Events
• Patient Outcome Registry Data
  • Design:
    • EO1 - EO5 Studies
    • VNS as Adjunctive Therapy
  • Patients:
    • 60 Patients <19 YO, including 16 <12 YO
    • Partial Seizures: 73%, Primary Generalized Seizures: 27%
    • Mean Age: 13.5 YO
    • Prior CNS Surgery: 25%

• VNS Adolescent Data (EO1-EO5) Conclusion:
  • Chronic stimulation of the left vagal nerve in children with pharmacoresistant epilepsy is associated with a reduction in seizure frequency, similar to what has been reported in adults.
  • Adverse events do not appear unusual following this surgical intervention. The observed adverse advents did not necessitate cessation of stimulation.

• VNS Post Approval vs. Seizures: Under Age 18

• VNS Post Approval Quality of Life: Under Age 18